Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
Dateline City:
KENILWORTH, N.J. Phase 2 Data Presentations at The Liver Meeting® Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously FailedKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced the presentation of results from three Phase 2 clinical
trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1),
the company ’s investigational all-oral, triple-combination regimen for
the treatment of chronic hepatitis C (HCV) infection (informally
referred to as MK3).Language:
EnglishContact: Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK MSD Source Type: news
More News: Clinical Trials | Hepatitis | Hepatitis C | Liver | Merck | Pharmaceuticals | Study | Urology & Nephrology | Virology